The people
What they build
Open roles via the TechTO Job Board
Working at Aspect Biosystems
Browse open roles across the community on the TechTO Job Board — Canada’s most connected tech network. Aspect Biosystems’s roles show up here whenever they post.
Open roles on the TechTO Job Board ↗Or their own careers page: aspectbiosystems.com/careers ↗Jobs live on jobs.techto.org — the only structured source. We link to it rather than scraping career sites, so the board is always the source of truth.
On the TechTO & TechVancouver stages
The Journey of Creating Human Tissues on Demand
Watch on YouTube ↗Transforming the Future of Medicine
Watch on YouTube ↗Every talk is searchable — ask the archive about Aspect Biosystems ↗
About
Aspect Biosystems began in a UBC lab and was in the first cohort of the entrepreneurship@UBC program — Tamer Mohamed calls the team the guinea pigs of that program. The company's mission, as he puts it on the TechTO stage, is bioprinted tissue therapeutics: living tissues implanted inside the body to replace damaged function. Its lead programme is a pancreatic tissue implant for type 1 diabetes that senses glucose and releases insulin; it is also working on printed liver tissue as a bridge to transplant. Novo Nordisk partnered with it in 2023, and a US$115M Series B led by Dimension followed in January 2025. In January 2026 the two went further: Aspect took rights to Novo Nordisk's stem cell-derived islet cell and hypoimmune cell engineering technologies, absorbed select Novo cell-therapy research, development and manufacturing capability from the US and Denmark into its Canadian platform, and took the lead on development, manufacturing and commercialisation. Novo made a further equity investment and keeps defined rights to step back into later-stage work. No figures were disclosed.
Backers
Dimension led the US$115M Series B, with Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures and the T1D Fund participating. The Government of Canada and the Province of BC are non-dilutive partners.
More from TechTO ×6
Quick answers
What does Aspect Biosystems do?
It bioprints living tissues that are implanted in the body to replace function lost to disease — rather than printing tissue for lab testing. Its lead programme is a pancreatic implant for type 1 diabetes that senses glucose and releases insulin.
Who founded Aspect Biosystems?
Tamer Mohamed, Sam Wadsworth, Simon Beyer and Konrad Walus, out of Walus's lab at UBC in 2013. Walus was CEO until 2016, when Mohamed moved from CTO to CEO.
How much has Aspect Biosystems raised?
Over US$350M, including a US$115M Series B led by Dimension in January 2025. In April 2026 it announced a $280M multi-year partnership with the Government of Canada that includes $79M in federal funding.